These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 3032378

  • 1. Prevention of parathyroid hormone-dependent nephrocalcinosis by chronic administration of the organic phosphorothioate WR-2721.
    Hirschel-Scholz S, Caverzasio J, Bonjour JP.
    Calcif Tissue Int; 1987 Feb; 40(2):103-8. PubMed ID: 3032378
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent.
    Hirschel-Scholz S, Caverzasio J, Bonjour JP.
    J Clin Invest; 1985 Nov; 76(5):1851-6. PubMed ID: 2997292
    [Abstract] [Full Text] [Related]

  • 3. Protection from progressive renal failure and hyperparathyroid bone remodeling by WR-2721.
    Hirschel-Scholz S, Charhon S, Rizzoli R, Caverzasio J, Paunier L, Bonjour JP.
    Kidney Int; 1988 May; 33(5):934-41. PubMed ID: 2839727
    [Abstract] [Full Text] [Related]

  • 4. Interference of WR-2721 with magnesium metabolism: mechanism of action.
    Hirschel-Scholz S, Paunier L, Bonjour JP.
    Miner Electrolyte Metab; 1988 May; 14(2-3):114-20. PubMed ID: 2837628
    [Abstract] [Full Text] [Related]

  • 5. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.
    Hirschel-Scholz S, Caverzasio J, Rizzoli R, Bonjour JP.
    J Clin Invest; 1986 Jul; 78(1):319-22. PubMed ID: 3013941
    [Abstract] [Full Text] [Related]

  • 6. Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells.
    Attie MF, Fallon MD, Spar B, Wolf JS, Slatopolsky E, Goldfarb S.
    J Clin Invest; 1985 Apr; 75(4):1191-7. PubMed ID: 2985652
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of phosphorus on endogenous calcium losses during total parenteral nutrition.
    Wood RJ, Sitrin MD, Rosenberg IH.
    Am J Clin Nutr; 1988 Sep; 48(3):632-6. PubMed ID: 2843026
    [Abstract] [Full Text] [Related]

  • 11. Resistance to the phosphaturic and calcemic actions of parathyroid hormone during phosphate depletion. Prevention by 1,25-dihydroxyvitamin D3.
    Gloor HJ, Bonjour JP, Caverzasio J, Fleisch H.
    J Clin Invest; 1979 Mar; 63(3):371-7. PubMed ID: 34630
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Influence of parathyroidectomy and calcium on rat renal function.
    Zaladek Gil F, Nascimento Gomes G, Cavanal MF, Cesar KR, Magaldi AJ.
    Nephron; 1999 Sep; 83(1):59-65. PubMed ID: 10461037
    [Abstract] [Full Text] [Related]

  • 15. In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.
    Weiss J, Walker ST, Fallon M, Goldfarb S.
    J Pharmacol Exp Ther; 1986 Sep; 238(3):969-73. PubMed ID: 3018229
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats.
    Rizzoli R, Caverzasio J, Chapuy MC, Martin TJ, Bonjour JP.
    J Bone Miner Res; 1989 Oct; 4(5):759-65. PubMed ID: 2554691
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.